US EditionAxoGen: Q4 Earnings Snapshot
- On Feb. 23, 2026 BioMarin announced full-year 2025 results and provided 2026 guidance, with revenues expected to be $3,325 to $3,425 million.
- VOXZOGO's sales surged, driving 17% total revenue growth in 2025, while Enzyme Therapies advanced 9%, supported by PALYNZIQ, and BioMarin expanded VOXZOGO CANOPY with five new indications.
- Full-Year GAAP results show a net loss of $ million, while non-GAAP results reported $47.7 million net income and a 16.5% gross margin for 2025.
- The acquisition of Amicus Therapeutics, expected to close in Q2'26, includes $3.7 billion in financing, and management expects a Non‑GAAP Operating Margin of approximately 40% for 2026, excluding the post-close impact.
- Upcoming regulatory dates include a PALYNZIQ U.S. PDUFA date on February 28, 2026, and other 1H'26 program milestones; the press release contains extensive forward‑looking statements subject to risks, BioMarin said.
125 Articles
125 Articles
Rackspace Technology Reports Fourth Quarter and Full Year 2025 Results
Fourth Quarter Revenue of $683 million, down 0.4% Year-over-Year; 2025 Revenue of $2,686 million, down 2% Year-over-YearFourth Quarter Private Cloud Revenue of $241 million, down 10% Year-over-Year; 2025 Private Cloud Revenue of $990 million, down 6% Year-over-YearFourth Quarter Public Cloud…
SEACOR Marine Announces Fourth Quarter 2025 Results
HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- SEACOR Marine Holdings Inc. (NYSE: SMHI) (the “Company” or “SEACOR Marine”), a leading provider of marine and support transportation services to offshore energy facilities worldwide, today announced results for its fourth quarter ended…
The Record
Simcoe.comOTC Markets Group Announces Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM) today announced it will report its financial results for the fourth quarter and fiscal year ended December 31, 2025, after the close of the U.S. capital…
Coverage Details
Bias Distribution
- 59% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
